449 related articles for article (PubMed ID: 25727149)
21. Identifying N-Glycan Biomarkers in Colorectal Cancer by Mass Spectrometry.
Sethi MK; Hancock WS; Fanayan S
Acc Chem Res; 2016 Oct; 49(10):2099-2106. PubMed ID: 27653471
[TBL] [Abstract][Full Text] [Related]
22. N-glycomic profiling as a tool to separate rectal adenomas from carcinomas.
Kaprio T; Satomaa T; Heiskanen A; Hokke CH; Deelder AM; Mustonen H; Hagström J; Carpen O; Saarinen J; Haglund C
Mol Cell Proteomics; 2015 Feb; 14(2):277-88. PubMed ID: 25452313
[TBL] [Abstract][Full Text] [Related]
23. Specific (sialyl-)Lewis core 2
Madunić K; Mayboroda OA; Zhang T; Weber J; Boons GJ; Morreau H; van Vlierberghe R; van Wezel T; Lageveen-Kammeijer GSM; Wuhrer M
Theranostics; 2022; 12(10):4498-4512. PubMed ID: 35832079
[TBL] [Abstract][Full Text] [Related]
24. Identification of O-Linked Glycoproteins Binding to the Lectin Helix pomatia Agglutinin as Markers of Metastatic Colorectal Cancer.
Peiris D; Ossondo M; Fry S; Loizidou M; Smith-Ravin J; Dwek MV
PLoS One; 2015; 10(10):e0138345. PubMed ID: 26495974
[TBL] [Abstract][Full Text] [Related]
25. Highly fucosylated N-glycan ligands for mannan-binding protein expressed specifically on CD26 (DPPVI) isolated from a human colorectal carcinoma cell line, SW1116.
Kawasaki N; Lin CW; Inoue R; Khoo KH; Kawasaki N; Ma BY; Oka S; Ishiguro M; Sawada T; Ishida H; Hashimoto T; Kawasaki T
Glycobiology; 2009 Apr; 19(4):437-50. PubMed ID: 19129245
[TBL] [Abstract][Full Text] [Related]
26. Mass spectrometry analysis reveals aberrant N-glycans in colorectal cancer tissues.
Zhang D; Xie Q; Wang Q; Wang Y; Miao J; Li L; Zhang T; Cao X; Li Y
Glycobiology; 2019 May; 29(5):372-384. PubMed ID: 30698702
[TBL] [Abstract][Full Text] [Related]
27. Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.
Ferdosi S; Rehder DS; Maranian P; Castle EP; Ho TH; Pass HI; Cramer DW; Anderson KS; Fu L; Cole DEC; Le T; Wu X; Borges CR
J Proteome Res; 2018 Jan; 17(1):543-558. PubMed ID: 29129073
[TBL] [Abstract][Full Text] [Related]
28. N-glycomic profiling of colorectal cancer according to tumor stage and location.
Holm M; Nummela P; Heiskanen A; Satomaa T; Kaprio T; Mustonen H; Ristimäki A; Haglund C
PLoS One; 2020; 15(6):e0234989. PubMed ID: 32598367
[TBL] [Abstract][Full Text] [Related]
29. Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.
Cotton S; Azevedo R; Gaiteiro C; Ferreira D; Lima L; Peixoto A; Fernandes E; Neves M; Neves D; Amaro T; Cruz R; Tavares A; Rangel M; Silva AMN; Santos LL; Ferreira JA
Mol Oncol; 2017 Aug; 11(8):895-912. PubMed ID: 28156048
[TBL] [Abstract][Full Text] [Related]
30. Glycoengineered cell models for the characterization of cancer O-glycoproteome: an innovative strategy for biomarker discovery.
Campos D; Freitas D; Gomes J; Reis CA
Expert Rev Proteomics; 2015 Aug; 12(4):337-42. PubMed ID: 26098314
[TBL] [Abstract][Full Text] [Related]
31. Compensation of loss of protein function in microsatellite-unstable colon cancer cells (HCT116): a gene-dependent effect on the cell surface glycan profile.
Patsos G; André S; Roeckel N; Gromes R; Gebert J; Kopitz J; Gabius HJ
Glycobiology; 2009 Jul; 19(7):726-34. PubMed ID: 19293232
[TBL] [Abstract][Full Text] [Related]
32. Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives.
Chia J; Goh G; Bard F
Biochim Biophys Acta; 2016 Aug; 1860(8):1623-39. PubMed ID: 26968459
[TBL] [Abstract][Full Text] [Related]
33. Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer.
Mereiter S; Magalhães A; Adamczyk B; Jin C; Almeida A; Drici L; Ibáñez-Vea M; Gomes C; Ferreira JA; Afonso LP; Santos LL; Larsen MR; Kolarich D; Karlsson NG; Reis CA
Biochim Biophys Acta; 2016 Aug; 1860(8):1795-808. PubMed ID: 26721331
[TBL] [Abstract][Full Text] [Related]
34. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis.
Zhao J; Qiu W; Simeone DM; Lubman DM
J Proteome Res; 2007 Mar; 6(3):1126-38. PubMed ID: 17249709
[TBL] [Abstract][Full Text] [Related]
35. Investigations on aberrant glycosylation of glycosphingolipids in colorectal cancer tissues using liquid chromatography and matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF-MS).
Holst S; Stavenhagen K; Balog CI; Koeleman CA; McDonnell LM; Mayboroda OA; Verhoeven A; Mesker WE; Tollenaar RA; Deelder AM; Wuhrer M
Mol Cell Proteomics; 2013 Nov; 12(11):3081-93. PubMed ID: 23878401
[TBL] [Abstract][Full Text] [Related]
36. Cystic fibrosis and bacterial colonization define the sputum N-glycosylation phenotype.
Venkatakrishnan V; Thaysen-Andersen M; Chen SC; Nevalainen H; Packer NH
Glycobiology; 2015 Jan; 25(1):88-100. PubMed ID: 25190359
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Glycomics of a Multistep Human Brain Tumor Model Reveals Specific Glycosylation Patterns Related to Malignancy.
Furukawa J; Tsuda M; Okada K; Kimura T; Piao J; Tanaka S; Shinohara Y
PLoS One; 2015; 10(7):e0128300. PubMed ID: 26132161
[TBL] [Abstract][Full Text] [Related]
38. Glycosylation profiles of the human colorectal cancer A33 antigen naturally expressed in the human colorectal cancer cell line SW1222 and expressed as recombinant protein in different insect cell lines.
Joosten CE; Cohen LS; Ritter G; Batt CA; Shuler ML
Biotechnol Prog; 2004; 20(4):1273-9. PubMed ID: 15296462
[TBL] [Abstract][Full Text] [Related]
39. Mass Spectrometry-Based N-Glycomics of Colorectal Cancer.
Sethi MK; Fanayan S
Int J Mol Sci; 2015 Dec; 16(12):29278-304. PubMed ID: 26690136
[TBL] [Abstract][Full Text] [Related]
40. Alterations in glycosylation as biomarkers for cancer detection.
Reis CA; Osorio H; Silva L; Gomes C; David L
J Clin Pathol; 2010 Apr; 63(4):322-9. PubMed ID: 20354203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
